AtG Therapeutics was launched to develop a portfolio of medicines for advanced cancers, initially focusing on therapies tied to a metabolic tumor target and a patient selector. The company will start with two programs: AtG 153, already in preclinical studies with animal models, and AngioDxPredict, which is in prototype development. Founders and senior team combine academic research expertise and industry experience to advance translational oncology assets. Initial indications targeted include renal, colorectal and breast cancers. The company intends to expand the initial portfolio into additional R&D programs for multiple oncologic indications. AtG emphasizes precision-medicine approaches to identify patients most likely to benefit from its treatments.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2022